[go: up one dir, main page]

ZA94248B - Potentiation of temozolomide in human tumour cells - Google Patents

Potentiation of temozolomide in human tumour cells

Info

Publication number
ZA94248B
ZA94248B ZA94248A ZA94248A ZA94248B ZA 94248 B ZA94248 B ZA 94248B ZA 94248 A ZA94248 A ZA 94248A ZA 94248 A ZA94248 A ZA 94248A ZA 94248 B ZA94248 B ZA 94248B
Authority
ZA
South Africa
Prior art keywords
potentiation
temozolomide
tumour cells
human tumour
human
Prior art date
Application number
ZA94248A
Other languages
English (en)
Inventor
John Colin Baer
Edward Stuart Newlands
Joseph Anthony Rafferty
Azadeh Alison Freeman
Amanda Jean Watson
Geoffrey Paul Margison
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Publication of ZA94248B publication Critical patent/ZA94248B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA94248A 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells ZA94248B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US475493A 1993-01-14 1993-01-14

Publications (1)

Publication Number Publication Date
ZA94248B true ZA94248B (en) 1994-07-13

Family

ID=21712364

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94248A ZA94248B (en) 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells

Country Status (20)

Country Link
EP (2) EP0679086A1 (uk)
JP (1) JPH08505615A (uk)
KR (1) KR100352046B1 (uk)
CN (1) CN1277541C (uk)
AU (1) AU5838494A (uk)
CA (1) CA2153775C (uk)
CZ (1) CZ286550B6 (uk)
FI (1) FI953423L (uk)
HU (1) HUT72665A (uk)
IL (1) IL108328A (uk)
MX (1) MX9400434A (uk)
MY (1) MY116474A (uk)
NO (1) NO952781L (uk)
PL (1) PL175842B1 (uk)
RU (1) RU2148401C1 (uk)
SK (1) SK282452B6 (uk)
TW (1) TW414710B (uk)
UA (1) UA29466C2 (uk)
WO (1) WO1994015615A1 (uk)
ZA (1) ZA94248B (uk)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
PE20001320A1 (es) * 1998-12-07 2000-12-06 Schering Corp Uso de composiciones microcristalinas de temozolomida en el tratamiento de canceres
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
CN101172104B (zh) * 2002-02-22 2013-04-03 默沙东公司 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途
DE60331458D1 (de) * 2002-05-31 2010-04-08 Transmolecular Inc Kombinationschemotherapie mit chlorotoxin
CN100366249C (zh) * 2002-09-29 2008-02-06 天津帝士力投资控股集团有限公司 一种替莫唑胺控释给药系统
CN1752088A (zh) * 2004-09-22 2006-03-29 天津市金士力药物研究开发有限公司 含有替莫唑胺酯的药用组合物
CN100431605C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100402091C (zh) * 2005-02-03 2008-07-16 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100350974C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
RU2318509C2 (ru) * 2006-02-10 2008-03-10 Всеволод Иванович Киселев Твердая лекарственная форма дииндолилметана для лечения неопластических заболеваний
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
WO2009140599A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
CN103169664B (zh) * 2011-12-25 2015-04-22 复旦大学 一种rgd肽修饰的双层载药纳米粒及其制备方法
BR112015013525A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352669A (en) * 1990-03-13 1994-10-04 The Of The United States Of America As Represented By The Department Of Health And Human Services O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity

Also Published As

Publication number Publication date
FI953423A7 (fi) 1995-08-23
CA2153775C (en) 2000-11-14
MX9400434A (es) 1994-07-29
EP0679086A1 (en) 1995-11-02
IL108328A0 (en) 1994-04-12
FI953423A0 (fi) 1995-07-13
MY116474A (en) 2004-02-28
PL309915A1 (en) 1995-11-13
CZ179795A3 (en) 1996-04-17
SK282452B6 (sk) 2002-02-05
CN1277541C (zh) 2006-10-04
FI953423L (fi) 1995-08-23
UA29466C2 (uk) 2000-11-15
PL175842B1 (pl) 1999-02-26
HU9502117D0 (en) 1995-09-28
EP0922458A1 (en) 1999-06-16
KR100352046B1 (ko) 2003-09-03
SK89295A3 (en) 1996-06-05
WO1994015615A1 (en) 1994-07-21
NO952781L (no) 1995-09-13
KR960700063A (ko) 1996-01-19
JPH08505615A (ja) 1996-06-18
IL108328A (en) 2010-05-31
CA2153775A1 (en) 1994-07-21
CN1117711A (zh) 1996-02-28
TW414710B (en) 2000-12-11
AU5838494A (en) 1994-08-15
HUT72665A (en) 1996-05-28
CZ286550B6 (cs) 2000-05-17
RU2148401C1 (ru) 2000-05-10
NO952781D0 (no) 1995-07-13

Similar Documents

Publication Publication Date Title
IL108328A0 (en) Potentiation of temozolomide in human tumour cells
AU7623096A (en) Use of epinastine in the treatment of pain
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
HUP9801634A3 (en) Genetically modified cells and their use in prevention or therapy of disease
AU4786093A (en) Non-peptidic surrogates of the ldv sequence and their use in the treatment of inflammation, autoimmune diseases and tumour progression
SG47041A1 (en) In vitro-derived human neutrophil precursor cells
IL116966A0 (en) Bicyclic isothiourea derivatives useful in therapy
GB2281863B (en) Improvements in relation to medical diathermy
AU2975692A (en) Expression vectors and their use in the preparation of HIV-resistant human cells for therapeutic applications
ZA943549B (en) Cell surface protein expressed on human cortical thymocyte and their use
ZA95508B (en) Use of flavolignans as adjuvants in tumour therapy
AU6371198A (en) Potentiation of temozolomide in human tumour cells
AU4980693A (en) Improvements in skin plasters
GB9721075D0 (en) Materials and methods relating to the stimulation of cells
ZA941939B (en) Therapeutic triazine compounds and use
GB9523066D0 (en) Compounds and their therapeutic use
GB9305693D0 (en) Therapeutic triazine compounds and use
GB9312780D0 (en) Therapeutic and cosmetic treatment
SI1011649T1 (en) Use of endipalene in the treatment of psoriasis
GB9316836D0 (en) Human cell lines
ZA96972B (en) Bicyclic isothiourea derivatives useful in therapy
IL105012A0 (en) Skin treatment gel
PL293676A1 (en) Watch designed to indicate various physiological biorythms in particular human ones
IL112179A0 (en) Generation of human insulin
ZA964000B (en) Xanthines and their therapeutic use